Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk
Eli Lilly shares closed at $1,071.44 on Friday, Dec. 19, up 4.3% from the previous week. The company’s stock remains near record highs as late-stage trial data showed its oral obesity drug orforglipron helped patients maintain weight loss after switching from injectables. Reuters reported the FDA is considering a faster review timeline for orforglipron.